RxDoctor Payments Data

Michaela Machurick

Nurse Practitioner · Green Bay, WINPI 1366137333

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 35 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$179
  • Boston Scientific$140
  • Actelion Pharmaceuticals US, Inc.$139
  • Novartis$125
  • Alnylam Pharmaceuticals Inc.$110
  • Pfizer$85
  • plus $225 from 8 others

What the payments were for

  • Food & beverage$1,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,004 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$26,535
Medicare patients
226
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban217$224,056
JardianceEmpagliflozin44$44,056
XareltoRivaroxaban30$44,022
EntrestoSacubitril/Valsartan40$43,553
BrilintaTicagrelor22$11,057
Prasugrel Hcl18$3,865
Metoprolol Succinate203$3,297
Atorvastatin Calcium148$2,119
Amiodarone Hcl34$1,910
Furosemide235$1,629
Metoprolol Tartrate201$1,618
ClopidogrelClopidogrel Bisulfate111$1,448
Spironolactone169$1,313
Lisinopril122$1,181
Isosorbide Mononitrate ErIsosorbide Mononitrate100$1,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$224,056217 claims
Boehringer IngelheimJardiance$32$44,05644 claims
Johnson & JohnsonXarelto$60$44,02230 claims
NovartisEntresto$125$43,55340 claims
AstraZenecaBrilinta$13$11,05722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →